Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.

Autor: Hughes, Derralynn A., Nicholls, Kathleen, Sunder‐Plassmann, Gere, Jovanovic, Ana, Feldt‐Rasmussen, Ulla, Schiffmann, Raphael, Giugliani, Robert, Jain, Vipul, Viereck, Chris, Castelli, Jeffrey P., Skuban, Nina, Barth, Jay A., Bichet, Daniel G.
Zdroj: American Journal of Medical Genetics. Part A; Jun2019, Vol. 179 Issue 6, p1069-1073, 5p
Databáze: Complementary Index
Externí odkaz: